The QualityStocks Daily Monday, April 24th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(INAB) $3.0000 +185.71%

MarketBeat(IDYA) $20.2600 +35.70%

InvestorsUnderground(SFR) $2.0000 +33.33%

The QualityStocks Daily Stock List

Sonendo Inc. (SONX)

QualityStocks, The Stock Dork and MarketBeat reported earlier on Sonendo Inc. (SONX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonendo Inc. (NYSE: SONX) is a commercial-stage medical technology firm that is focused on the development, manufacture and commercialization of devices for root canal therapy.

The firm has its headquarters in Laguna Hills, California and was incorporated in 2006. Prior to its name change in March 2011, the firm was known as Dentatek Corp. It operates as part of the medical devices industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe, with a focus on Canada and the United States.

The company’s mission is to save teeth and prevent the progression of tooth decay. It does so by enabling superior disinfection and cleaning of the root canal system with a streamlined workflow for practices and minimal post-operative pain for individuals.

The enterprise provides a practice management software known as the Digital Office, which enables an integrated digital office for dental practitioners. It also provides a material used to create a seal platform on top of the tooth crown, dubbed SoundSeal; and a branded EDTA liquid solution which is used to help disinfect the root canal system. In addition to this, the enterprise offers a tooth decay treatment device for disinfecting and cleaning the microscopic spaces between teeth known as GentleWave.

The firm is focused on increasing the adoption of its GentleWave System, which has numerous clinical benefits, especially in comparison to current methods of root canal therapy. This will not only bring in additional revenues but also extend its consumer reach, which will positively influence investments.

Sonendo Inc. (SONX), closed Monday's trading session at $1.77, up 30.1471%, on 132,346 volume. The average volume for the last 3 months is 33.172M and the stock's 52-week low/high is $0.86/$3.35.

Ucloudlink Group (UCL)

StreetInsider, QualityStocks, StocksEarning, StockEarnings, MarketClub Analysis and FreeRealTime reported earlier on Ucloudlink Group (UCL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ucloudlink Group Inc. (NASDAQ: UCL) is a mobile data traffic sharing marketplace engaged in the provision of wireless telecommunication services.

The firm has its headquarters in Kowloon, Hong Kong and was incorporated in 2014, on August 25th by Zhi Ping Peng and Chao Hui Chen. It operates in the communications sector, under the telecommunications industry. The firm has seven companies in its corporate family and serves consumers around the globe.

The company is focused on providing premium user experience by offering a reliable, safe and dynamic network based on its patented and universal Cloud SIM technology. Its services and products offer unique value propositions to mobile network operators, mobile virtual network operators, smart-hardware companies and mobile data users.

The enterprise’s products include a model focused on cross-border travelers who need mobile data connectivity services in different jurisdictions, known as uCloudlink 1.0; and a model that offers mobile data connectivity services to local users via different mobile network operators, known as uCloudlink 2.0. It also provides a world phone series dubbed GlocalMe; uCloudlink 3.0, which includes B2B2C wholesale, B2C retail and software-as-a-service/platform-as-a-service platform-based connectivity ecosystem. The enterprise offers integrated network solutions to its customers; value added services; and SIM cards with prepaid data packages.

The company recently announced its latest financial results for 2021 which show increases in its total revenues. Its CEO noted that the increase observed was an indication that the company was well-positioned to grow due to its efforts to expand its platform-centric business. Currently, the company is focused on expanding its network and strengthening its collaborations with local partners.

Ucloudlink Group (UCL), closed Monday's trading session at $4.425, up 15.0845%, on 180,196 volume. The average volume for the last 3 months is 2.595M and the stock's 52-week low/high is $0.46/$6.60.

Rezolute Inc. (RZLT)

QualityStocks, MarketBeat, FreeRealTime and BUYINS.NET reported earlier on Rezolute Inc. (RZLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rezolute Inc. (NASDAQ: RZLT) is a clinical-stage biopharmaceutical firm that is engaged in the development of transformative therapies for metabolic illnesses linked to chronic glucose imbalance.

The firm has its headquarters in Redwood City, California and was incorporated in 2010, on July 26th by Sankaram Mantripragada, Ho Young Huh and Nevan Charles Elam. Prior to its name change in December 2017, the firm was known as AntriaBio Inc. It operates as part of the pharmaceutical and medicine manufacturing industry under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe, with a focus on the United States.

The company develops new, sustained-release injectable therapies. It applies proprietary manufacturing capabilities to well-characterized molecules to create patent-protected therapies which have the potential to improve current standards of care significantly.

The enterprise’s product candidates include a potent and selective plasma kallikrein inhibitor known as RZ402, which is undergoing phase 1 clinical trials testing its effectiveness in treating diabetic macular edema. It also develops an injectable basal insulin dubbed AB101 for type 1 and 2 diabetes, as well as a human monoclonal antibody dubbed RZ358, which is in phase 2b clinical trials evaluating its efficacy in treating a rare pediatric genetic disorder known as congenital hyperinsulinism.

The firm recently released its latest financial results, with its CEO noting that they remained focused on positioning the firm well to achieve its clinical milestones and advance its programs in order to develop alternative treatment options for various indications.

Rezolute Inc. (RZLT), closed Monday's trading session at $2.12, up 10.9948%, on 595,862 volume. The average volume for the last 3 months is 70,868 and the stock's 52-week low/high is $1.3401/$4.00.

Accelerate Diagnostics (AXDX)

The Street, MarketBeat, QualityStocks, InvestorPlace,, Money Morning, StreetInsider, Schaeffer's, CustomerService, TradersPro, Barchart, Market Report, Kiplinger Today, StockMarketWatch, Agora Financial, Money Wealth Matters, Trader Prep, Street Insider, Daily Trade Alert, Daily Market Beat, Schaeffer’s, Shah's Insights & Indictments and StreetAuthority Daily reported earlier on Accelerate Diagnostics (AXDX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Accelerate Diagnostics Inc. (NASDAQ: AXDX) (FRA: 1AB) (BMV: AXDX) is an in vitro diagnostics firm that is engaged in the provision of solutions for diagnosing severe bacterial infections.

The firm has its headquarters in Tucson, Arizona and was incorporated in 1982, on May 26th. Prior to its name change in December 2012, the firm was known as Accelr8 Technology Corp. The firm serves consumers in the Middle East, Europe and the United States, as well as the worldwide healthcare sector.

The company’s platform, the Accelerate ID/AST system, is used to determine if live fungal or bacterial cells observed in a sample are defenseless against a specific antibiotic. The system can also analyze positive blood culture samples in about 5 hours, which is faster, in comparison with conventional testing methods.

The enterprise offers a test kit for its system known as the Accelerate PhenoTest, which identifies and tests for antibiotic susceptibility in patients who may have fungemia or bacteremia, which are both life-threatening conditions with high mortality and morbidity risk. In addition to this, it provides an in vitro diagnostic platform known as the Accelerate Pheno system, which identifies and tests for antibiotic susceptibility of pathogens linked to severe healthcare-associated infections including gram-negative and gram-positive organisms.

The firm’s new IVD Accelerate PhenoTest BC kit configuration was recently CE marked and will soon be available in Europe. This move not only offers options that accommodate the different lab and clinical settings in Europe but will also extend the firm’s consumer reach, which may in turn boost its growth.

Accelerate Diagnostics (AXDX), closed Monday's trading session at $0.7889, up 14.3333%, on 885,555 volume. The average volume for the last 3 months is 709,999 and the stock's 52-week low/high is $0.4501/$3.737.

Thinkific Labs (THNCF)

MarketBeat reported earlier on Thinkific Labs (THNCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Thinkific Labs Inc. (OTC: THNCF) (TSE: THNC) (FRA: 5S0) is a company focused on developing, marketing and providing support management for cloud-based platforms globally.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2012, on April 11th by Matthew Smith, Greg Smith, Matt Payne and Miranda Lievers. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe, with a main focus on those in the United States and Canada.

The company’s mission is to revolutionize the way individuals learn and earn online by giving them the tools needed to turn their expertise into a sustainable business that impacts both them and their audience. Its primary business activity is to provide a platform that helps entrepreneurs and established businesses to scale and generate revenue by teaching what they know.

The enterprise platform provides its creators with the functionality needed to launch, grow, and diversify their businesses by creating and selling online courses and other learning products comprised of customized courses, communities, membership sites, and other experiences that its creators can create, sell and deliver using the Platform (collectively, Learning Products). Its features include creating amazing courses, building websites to market your business, generate income by selling, engage with your learning community, and grow and scale your business.

The firm recently launched a customizable app solution dubbed Branded Mobile, a move that affords creators advanced tools to build and scale their online businesses while also extending the firm’s consumer reach.

Thinkific Labs (THNCF), closed Monday's trading session at $1.9, even for the day, on 48 volume. The average volume for the last 3 months is 246,928 and the stock's 52-week low/high is $1.0853/$1.96.

Silver Elephant Mining (SILEF)

We reported earlier on Silver Elephant Mining (SILEF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Silver Elephant Mining Corp (OTCQX: SILEF) (TSE: ELEF) (FRA: 1P2) is a mineral exploration stage firm that is focused on acquiring, exploring for and developing mineral and energy projects.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1978, on November 6th. Prior to its name change in March 2020, the firm was known as Prophecy Development Corp. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm primarily serves consumers in Canada.

The company explores for nickel, gold, lead, silver, titanium, zinc, vanadium, iron and coal. Geographically, it operates in the United States, Canada, Bolivia, and Mongolia.

The enterprise’s flagship project is the Pulacayo project, a silver-lead-zinc property located in Bolivia which comprises of the Pulacayo Deposit and Paca Deposit (found 7km north of Pulacayo deposit). Its other projects include the Minago nickel property in Canada (the Minago Project); the Gibellini vanadium property in Nevada, United States (the Gibellini Project); and the El Triunfo gold-silver-lead-zinc project in Bolivia (the Triunfo Project). The enterprise also holds 100% interest in a range of projects, including the Titan vanadium-titanium-iron project located in Ontario, Canada; the Tal and Chandgana Khavtgai coal projects located in Mongolia; and the Ulaan Ovoo coal project in Mongolia, which it operates through its Mega Thermal Coal Corp subsidiary.

The firm recently appointed a new VP of Exploration with decades of experience in mining exploration and development of precious and base metals projects, a move that may positively influence its production as well as overall growth.

Silver Elephant Mining (SILEF), closed Monday's trading session at $0.3954, off by 0.327704%, on 16,668 volume. The average volume for the last 3 months is 338,198 and the stock's 52-week low/high is $0.2586/$0.94.

bluebird bio (BLUE)

The Street, MarketBeat, MarketClub Analysis, StreetInsider, Schaeffer's, Trades Of The Day, Kiplinger Today, Daily Trade Alert, InvestorPlace,, StreetAuthority Daily, The Best Newsletters, TopStockAnalysts, BUYINS.NET, Zacks, StockEarnings, The Online Investor, Wealth Insider Alert, Barchart, Investing Futures, InvestmentHouse, Investment U, VectorVest, TraderPower, Investopedia, AllPennyStocks, Street Insider, Stock Up Featured, Investment House, Investing Signal, Market Intelligence Center Alert, Market Report, Hit and Run Candle Sticks, Direction Alerts, Rick Saddler, DrStockPick, Average Joe Options, BestOtc, Streetwise Reports, Wealthpire Inc., Trader Jack, Total Wealth, TopPennyStockMovers, Top Pros' Top Picks, The Stock Dork, PennyToBuck, SwingTradeOnline, MarketWatch, StocksEarning, StockOodles, StockMarketWatch, Profit Confidential, PennyStockProphet, PennyOmega, PCG Advisory and SystemTrading reported earlier on bluebird bio (BLUE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

bluebird bio Inc. (NASDAQ: BLUE) (LON: 0HOH) (BMV: BLUE) is a biotechnology firm focused on researching, developing and commercializing potentially transformative gene therapies for serious genetic illnesses.

The firm has its headquarters in Somerville, Massachusetts and was incorporated in 1992, on April 16th by Ronald C. Dorazio and Philippe Leboulch. Prior to its name change in September 2010, the firm was known as Genetix Pharmaceuticals Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm primarily serves patients in the United States.

The company is party to a license agreement with Orchard Therapeutics Limited. Its revenue is derived from collaboration arrangements, license fees, research fees and grant revenue. The company works with strategic partners, industry peers and nonprofit organizations for the development and commercialization of its formulations.

The enterprise’s product pipeline is comprised of lovotibeglogene autotemcel (lovo-cel), which has been developed to treat sickle cell disease; ZYNTEGLO (betibeglogene autotemcel), a formulation developed to treat transfusion-dependent ß-thalassemia; and SKYSONA (elivaldogene autotemcel), for the treatment of cerebral adrenoleukodystrophy. Its clinical development programs include HGB-210, HGB-206 and HGB-205, which evaluate the safety and efficacy of lovo-cel in the treatment of patients with sickle cell disease SCD; and HGB-212, HGB-207, HGB-205 and HGB-204, to evaluate the safety and efficacy of beti-cel in treating patients with ß-thalassemia.

The firm, which has already received 2 FDA approvals for its Skysona and Zynteglo formulations, remains focused on receiving approval for commercialization for its lovo-cel formulation. Its approval will benefit patients with sickle cell disease while also bringing in additional investments into the firm.

bluebird bio (BLUE), closed Monday's trading session at $3.44, up 0.291545%, on 7,306,936 volume. The average volume for the last 3 months is 129,542 and the stock's 52-week low/high is $2.78/$8.58.

CeCors (CEOS)

PoliticsAndMyPortfolio, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, OTCtipReporter, MarketClub Analysis and CustomerService reported earlier on CeCors (CEOS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CeCors, Inc. (OTC: CEOS) is an innovative wellness company focused on the research, development and commercialization of adaptogenic, entheogenic and nootropic formulations and ingredients for its functional product lines to optimize and improve life.

The firm has its headquarters in Toronto, Canada and was incorporated in 2002, on April 16th. Prior to its name change in August 2021, the firm was known as PsyKey Inc. It operates as part of the medical instruments and supplies industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s optimal wellness strategy entails the development of tools that will help remove barriers and provide inclusivity for those who seek support services or healthcare professionals.

The enterprise is focused on the health and technology sector, primarily on the mental health market through its investment and development of its Telemedicine (TeleMed) Network connecting patients with medical professionals. It uses the same network through its CannMedLive, which assists medical marijuana candidates by connecting them with physicians that diagnose and suggest appropriate treatment. It also develops technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapies for the psychedelic market. The enterprise’s retail products include functional mushroom coffees and teas, single serve drink mixes and oral supplements.

The company recently completed its acquisition of VetComm Corp, a move that solidifies its entrance into the multi-billion dollar veteran benefits industry. This will in turn extend the company’s reach and help generate value for its shareholders.

CeCors (CEOS), closed Monday's trading session at $0.0415, up 0.120627%, on 167,664 volume. The average volume for the last 3 months is 145,703 and the stock's 52-week low/high is $0.0101/$0.0977.


QualityStocks, PennyStocks24, plrinvest, RedChip, SmallCapVoice, UndiscoveredEquities, TopPennyStockMovers, OTC Stock Review, AllPennyStocks, StocksEarning, MarketBeat,, Gladiator Stocks, Greenbackers, Penny Stock General, PennyPic, KillerPennyStocks, Ox of Wallstreet, OTCJournal, Penny Stock Alley, Free Penny Alerts, Free Investment Report, Explicit Penny Picks, Penny Stocks Expert, Shiznit Stocks, AwesomeStocks, Stockpicktrading, AwesomePennyStocks, The Green Baron, Titan Stocks, VictoryStocks, FeedBlitz, InsidersLab, M2 Communications, Penny Stock 101, alert, Penny Stock Titans, Wall Street Mover, PennyStockGains, PennyStockLocks, PennyStocksUniverse, PoliticsAndMyPortfolio, Small Cap Firm, StockRockandRoll, Streetwise Reports and Penny Stock Rumble reported earlier on SANUWAVE Health (SNWV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SANUWAVE Health Inc. (OTCQB: SNWV) is a shock wave technology firm that is focused on researching, developing and commercializing non-invasive, high-energy and acoustic shock waves for regenerative medicine and other applications.

The firm has its headquarters in Prairie, Minnesota and was incorporated in 2004, on May 6th. It operates as part of the medical devices industry, under the healthcare sector. The firm serves consumers across the globe, with a focus on those in the United States.

The company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration.

The enterprise's pulsed acoustic cellular expression systems, include its orthoPACE system for treating tendinopathies and acute and nonunion fractures; dermaPACE system for treating diabetic foot ulcers and other chronic wounds; and Profile, which offers therapeutic treatment of musculoskeletal conditions. In addition to this, it provides UltraMIST, a non-thermal and non-contact ultrasound therapy device developed for the treatment of pressure ulcers, diabetic foot ulcers, deep tissue pressure injuries, venous leg ulcers and surgical wounds. The enterprise’s UltraMIST and PACE systems are the only 2 FDA-approved directed energy systems for wound healing.

The company recently provided a corporate update of its operations, with its CEO noting that they remained focused on growing sales by increasing the supply of its products and achieving sustainable profitable growth. This will positively influence investments into the company as well as shareholder value.

SANUWAVE Health (SNWV), closed Monday's trading session at $0.0285, up 7.5472%, on 40,600 volume. The average volume for the last 3 months is 126,213 and the stock's 52-week low/high is $0.0014/$0.10.

Bit Digital Inc. (BTBT)

QualityStocks, MarketClub Analysis, StocksEarning, Schaeffer's, TradersPro, InvestorPlace, StockEarnings, MarketBeat, Daily Trade Alert and CryptoCurrencyWire reported earlier on Bit Digital Inc. (BTBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gary Gensler, the chairman of the Securities and Exchange Commission (SEC), received a torrent of criticism from Republican members of the House Financial Services Committee las week for the steps taken by his organization in pursuing cryptotrading companies.

In his more than four hours of grilling before the committee, Gensler remained adamant on the need for crypto exchanges and trading platforms to adhere to stringent U.S. securities rules.

The Republicans brought up many of the regulatory concerns that the cryptocurrency industry frequently raises, claiming that the SEC’s disclosure requirements were created to govern traditional markets and are therefore inappropriate for decentralized digital assets.

The businesses contend that if Congress doesn’t pass legislation that establishes a new legal framework expressly for cryptocurrencies, digital platforms would relocate abroad to avoid getting into trouble with American regulators. They argue that this might undermine the country’s position as a center of crypto innovation and could hand that advantage to its foes.

According to committee chairman Representative Patrick McHenry, R-N.C., the agency was punishing digital asset firms for laws they weren’t even aware they broke. Gensler, however, disputed the claim that crypto platforms lack legal knowledge regarding how to interpret American securities rules.

“There is an entire field in the crypto industry that can interpret the law with which they should comply if they are offering broker and exchange services or clearing services for cryptocurrency tokens,”  Gensler said.

In his testimony, Gensler refrained from going into detail about the facts of the SEC’s inquiry into the demise of FTX and, more recently, its notification to Coinbase that the cryptocurrency exchange is under probe. The SEC’s investigation into Coinbase first came to light midway through last year.

The SEC is cracking down on businesses and initiatives it claims are peddling unregistered securities as it steps up its action against the cryptocurrency sector.

In his Tuesday appearance before the House committee, Gensler showed little remorse for the difficulties that U.S.-based cryptocurrency exchanges must deal with. “Over the past 90 years, we have developed a clear regulatory framework,” he remarked. “The exchanges are just a group of intermediaries who believe they have a choice. They are powerless to resist. They must become compliant since they are frequently noncompliant.”

The possibility of lawmakers setting regulations for digital assets this year has receded, owing to the debt ceiling standoff and the House majority’s attention on matters such as energy and combating China’s multi-pronged threat.

Nevertheless, prominent cryptocurrency companies plan to spend money persuading Biden’s administration and Congress. All industry companies such as Bit Digital Inc. (NASDAQ: BTBT) will probably follow the developments on Capitol Hill as they await clarification on the regulatory framework for the industry.

Bit Digital Inc. (BTBT), closed Monday's trading session at $1.69, off by 5.5866%, on 2,493,917 volume. The average volume for the last 3 months is 2,700 and the stock's 52-week low/high is $0.5301/$2.33.

Alliance Resource Partners LP (ARLP)

The Online Investor, Zacks, QualityStocks, TradersPro, MarketBeat, The Street, InvestorPlace, MarketClub Analysis,, TopStockAnalysts, The Wealth Report, Dividend Opportunities, TheStockAdvisor, The Motley Fool, Money Morning, StreetAuthority Daily, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Early Bird, Daily Wealth, Daily Trade Alert, Rick Saddler, SmarTrend Newsletters, Wealth Insider Alert, Trading Concepts, The Growth Stock Wire, TheOptionSpecialist, TheStockAdvisors, TraderPower, TheTradingReport, Daily Markets, Trades Of The Day, Eagle Financial Publications, FNNO Newsletters, Greenbackers, Insider Wealth Alert, Top Pros' Top Picks,, Investor Update, Short Term Wealth, Leeb's Market Forecast, Louis Navellier, TheStreet Offers, MiningNewsWire, Money and Markets, StreetInsider, StockEarnings and Investment U reported earlier on Alliance Resource Partners LP (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Coal use in energy generation is poised to decline over the next few decades as dozens of countries worldwide transition to clean energy. The green-energy transition is part of a global movement to reduce greenhouse gas emissions and combat climate change by adapting renewable energies such as solar and wind that produce minimal to zero emissions.

While individuals are encouraged to take steps to reduce their carbon footprint, such as avoiding plastic packaging and reusing bags, action by large institutions will be necessary to cut down on greenhouse gas emissions on a large scale and achieve net zero emission goals.

Studies have shown that only 100 companies have been responsible for more than 70% of global greenhouse gas emissions since 1988, underscoring the need for renewable energy policies at the institutional level.

In 2021, Harvard Business School professors Daniel Green and Boris Vallée decided to analyze coal divestment policies in major banking institutions to determine if they affected coal emissions. Given that coal is without a doubt the dirtiest fossil fuel and it accounts for over one-fifth of all carbon dioxide emissions, reducing coal use would ultimately have a major impact on global C02 emissions.

The professors published a report indicating that green-energy policies within the financial sector have contributed to a drop in greenhouse gas emissions. The report showed that banking institutions play a significant role in the transition to renewable energy sources such as solar.

As it stands, the global coal industry is heavily reliant on capital from the banking sector, with research published by more than 25 NGOs indicating that banking institutions funneled an estimated $1.5 trillion to the coal industry from January 2019 to November 2021.

Coal divestment policies are designed to address climate change by reducing the sector’s investment in coal. Coal companies tend to limit their borrowing when faced with solid divestment policies from lenders in the banking sector, forcing them to reduce their operations and ultimately leading to a drop in carbon dioxide emissions.

According to Green and Vallée’s research, coal firms struggle to secure alternative funding when their historic lenders institute divestment policies.

The number of banks that already serve the coal industry is extremely limited and the relationships tend to be “so deeply entrenched” that banks hold an inordinate amount of power over which company gains funding.

Vallée noted that coal-fired power plants are more likely to retire when their traditional lenders pass bank divestment policies. As such, reducing the supply of capital to the coal industry can help to reduce carbon dioxide emissions by decreasing the number of operational coal-fired power plants.

As more funders withdraw their support from coal companies, miners such as Alliance Resource Partners LP (NASDAQ: ARLP) may have to pivot to other commodities in order to remain relevant in the decades to come.

Alliance Resource Partners LP (ARLP), closed Monday's trading session at $21.085, up 1.419%, on 381,476 volume. The average volume for the last 3 months is 5.76M and the stock's 52-week low/high is $14.54/$27.63.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scientists suggest that psychedelics are safe for use by older individuals when administered in a controlled setting. It should be noted that this safety profile hasn’t been confirmed for older individuals with chronic illnesses, including cardiovascular disease.

Estimates from the CDC show that roughly 60% of older people suffer from at least two chronic illnesses, with 75% of those aged 60 and above being hypertensive. Experts argue that these health challenges may contraindicate the use of psychedelics by older adults.

For their study, the researchers reviewed clinical trials from the last three decades that looked into MDMA and psilocybin-assisted therapies and their effectiveness in treating a range of conditions. Their objective was to determine whether psychedelic-assisted therapies could help relieve psychological distress in older people.

They found no reports of severe adverse reactions among older individuals who took part in the trials, noting that very few of those who received psychedelics were aged 60 and above, with most being relatively healthy. For example, when examining phase 1–3 trials on the effectiveness of MDMA-assisted therapy, the researchers found that the average age of participants was 41.

In their report, they highlighted that prior studies had discovered that certain psychedelics, such as psilocybin and MDMA, could cause arrhythmias as well as increase an individual’s blood pressure. The authors also called attention to one serious case of heart issues that was reported in a trial on MDMA-assisted therapy. Additionally, while a couple of trial participants experienced a spike in their blood pressure as expected, the researchers found no reports of strokes or heart attacks.

Brian Anderson, an assistant clinical professor of psychiatry at the University of California-San Francisco, explained that participants becoming hypertensive hadn’t been linked to neurological damage. Anderson, who was the senior author of the review, added that no discernible strokes had occurred in said participants.

The review’s lead, Professor C. Bree Johnston of the University of Arizona, added that the conditions studied, including depression brought on by a terminal disease, were relevant to the elderly. Johnston is also the director of palliative care at Skagit Regional Health.

The authors argued that the findings could also be extended to related conditions that hadn’t been studied, such as grief from a loved one’s death, which affects almost 10% of older individuals. They also underscore that their review wasn’t designed to be conclusive but exploratory. The authors published their findings in the “American Journal of Geriatric Psychiatry.

As efforts to develop psychedelic treatments continue by companies such as Seelos Therapeutics Inc. (NASDAQ: SEEL), the safety of these substances for different demographics is likely to become clearer.

Seelos Therapeutics Inc. (SEEL), closed Monday's trading session at $0.7, up 2.7146%, on 171,344 volume. The average volume for the last 3 months is 71.382M and the stock's 52-week low/high is $0.4803/$1.52.

The QualityStocks Company Corner

Starco Brands Inc. (OTCQB: STCB)

The QualityStocks Daily Newsletter would like to spotlight Starco Brands Inc. (OTCQB: STCB).

Starco Brands announced in March 2023 that Whipshots has sold overtwo million cans since its December 2021 launch

The company announced in February 2023 its acquisition of SoylentNutrition Inc., which pioneered the plant-based “completenutrition” and “functional food” categories

Soylent in March 2023 announced an expanded partnership with MeijerGrocery Stores, making its nutrition shakes available at hundredsof Meijer locations

Starco Brands in January 2023 entered into a definitive agreementto acquire Skylar, a maker of hypoallergenic fragrances that aresafe for sensitive skin

Starco Brands (OTCQB: STCB) today announced that Whipshots(TM), the groundbreakingvodka-infused whipped cream, has won awards in two prestigiousspirit industry competitions. The whipped cream brand, developed incollaboration with global artist and icon Cardi B, received a“Rising Star Award” in Beverage Dynamics’ 2023 Growth Brands Awardsas well as four medals in the 2023 DB & SB Spring Blind Tastingas part of the Global Spirits Masters Competition. “We're ecstaticthat Whipshots has been recognized by both the Growth Brands Awardsand the DB & SB Spring Blind Tasting,” said David Dreyer, chiefmarketing officer of Starco Brands. “Receiving these honors isextremely rewarding and further showcases our product as adisruptor in the industry from a brand and taste standpoint.”

To view the full press release, visit

Starco Brands Inc. (OTCQB: STCB) is a modern-day invention factory. The company’s unwavering mission is to invent and acquire consumer products and brands with behavior-changing technologies that spark excitement in the everyday.

This consumer product company has grown from a couple million dollars in revenue to approximately $80M in revenue in one year.

The company has succeeded by identifying whitespaces in eight core consumer categories and then either: 1) leveraging its internal R&D capabilities and dedicated manufacturing network to invent new technologies and brands or 2) utilizing the management team’s extensive M&A experience to acquire brands that fill the industry void, delighting consumers and retailers alike.

Whether the brand is developed internally or acquired, the company employs a modern marketing playbook to ensure its brands are at the forefront of culture; garnering unprecedented media attention and engagement that supports a robust sales network.

Starco Brands’ core competencies are inventing technologies, acquiring companies, marketing, building trends, pushing awareness, penetrating media (social and otherwise) and executing cutting edge pull-through strategies with a roster of globally recognized celebrities, influencers and media and distribution partners.

A commitment to changing the way people approach everyday activities is innate in the company’s corporate DNA.

The company is based in Santa Monica, California.


Whereas other consumer products companies are content with evolution, Starco Brands has its mind set on creating a revolution across the industry. From disrupting the spirits industry with Whipshots, the world’s only vodka-infused whipped cream, to Soylent, the original food tech company, Starco Brands is putting the CPG world on notice. Its portfolio of brands includes:

  • Whipshots is a first-of-its-kind alcoholic whipped cream launched in 2021 with celebrity partner Cardi B. Consumers have embraced this boozy concoction, putting it on top of cocktails, coffees and desserts, or enjoying it straight from the can. In just over a year, the brand has sold over 2 MILLION cans, making it one of the fastest growing spirits in history.
  • Winona Pure gives consumers movie theatre popcorn in the comfort of their own homes. All the flavor and none of the additives is the story behind these all-natural, non-GMO popcorn seasoning sprays. A simple spray is all it takes to add the perfect pop of flavor to the classic theatre treat.
  • Art of Sport, co-founded by the great Kobe Bryant, is the number one body care brand for athletes. With a growing line of personal care products tested by the world’s greatest athletes, these daily skin essentials give consumers everything they need to feel fresh, stay protected and confident and perform at their peak every day.
  • Skylar is the first and only line of perfumes on the market that are hypoallergenic and safe for sensitive skin. With the strong support of industry titan Sephora, the brand has quickly attracted a loyal following.
  • Soylent is a technological feat. Originally funded by Google Ventures and Andreessen Horwitz, Soylent is dubbed as the world’s most perfect food. Made from sustainably grown plant-based ingredients, Soylent’s line of products is scientifically developed to provide all the functional ingredients, vitamins, minerals, fats, carbohydrates and protein that the body needs – all in convenient, delicious and affordable packages. Soylent’s innovative product line-up includes complete nutrition powders, ready-to-drink shakes, 100-calorie snack bars, high protein nutrition shakes and energy boosting nutrition shakes. Soylent was also the recipient of the 2023 Product of the Year Award by Kantar, a global leader in consumer research.

With award-winning marketing talent, Starco Brands develops robust, integrated marketing plans for every brand in its portfolio, ensuring an impactful presence across all verticals.

Market Outlook

Starco Brands’ varied brand portfolio gives it access to the growth of numerous product categories that are ripe for innovation.

Through its February 2023 acquisition of complete nutrition pioneer Soylent, Starco Brands is positioned to capitalize on the projected growth of the plant-based nutrition space. Research firm Statista valued the plant-based nutrition market at $29.4 billion in 2020 and forecasts its value at nearly $162 billion by 2030, representing a CAGR of 18.7% for the period.

Likewise, Starco Brands gained improved access to the global fragrance market through its January 2023 acquisition of Skylar. According to a report by Grand View Research, the global perfume market was valued at $50.85 billion in 2022 and is expected to grow to a value of nearly $80 billion by 2030, achieving a CAGR of 5.9% over the forecast period.

The company is primed to expand its access to other growth verticals as it advances on its path to invent and acquire behavior-changing technologies and brands.

Management Team

Ross Sklar is the CEO of Starco Brands. A chemical formulator by trade, he started his first company while still in college. Since 2004, he has made over a dozen acquisitions with multiple exits and controls an eclectic collection of industrial, household, personal care and food and beverage manufacturers covering many consumer-packaged goods categories.

Darin Brown is the Chief Operating Officer of Starco Brands. With over 20 years of experience in chemical manufacturing, business development, finance and mergers and acquisitions, he has scaled the company from the ground up. He oversees all internal operations for Starco Brands and is an integral liaison between the company and Mr. Sklar’s manufacturing facilities.

David Dreyer is Chief Marketing Officer of Starco Brands. With over 25 years of experience working with blue chip and startup brands, he oversees all marketing initiatives for the company. Mr. Dreyer comes to Starco having worked with such standout brands as Apple, Pepsi, Pizza Hut, Dr Pepper, Snapple, Infiniti, The GRAMMY’s, Honda and He is also a Professor of Advertising at USC’s Annenberg School for Communication.

Starco Brands Inc. (STCB), closed Monday's trading session at $0.122, even for the day. The average volume for the last 3 months is 30.767M and the stock's 52-week low/high is $0.0725/$0.265.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

Europe has recently increased their renewable energy productiontarget to account for 45% of overall energy consumption by 2030, upfrom 32% previously

The continent’s renewable energy ambitions will be underpinned byincreasing the production capacity of several clean energy sources– including biomethane or renewable natural gas

EverGen Infrastructure have been at the forefront of growingCanada’s RNG output in recent years, with a goal to expand capacityto 480,000 GJ per annum in the near term

With RNG potentially classed as a ‘carbon negative’ energy source,expanding output of the gas ranks amongst the Canadian Government’skey energy priorities in coming years

Late in the evening on Thursday 31st March, European lawmakersreached a new consensus; by 2030, 45% of Europe’s overall energyconsumption will be powered by renewable energy, a necessary goalfor the continent to achieve its climate neutrality target by 2050( The target, which builds upon the prior goal of 32% set in 2018,will reinforce the need to increase the production output across awide array of clean energy sources – biogas and biomethane rankingchief amongst them.British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), has long operated at the forefront of Canada’s RNG industry,spearheading the effort to expand the nation’s RNG production. Thecompany has publicly announced a goal to own over 20 RNG-generatingfacilities across the country within five years; with four revenuegenerating assets already in operation, the company recentlyreiterated their ambition to grow their cumulative gross RNGgenerating capacity to 480,000 gigajoules of energy per annum inthe near future, a process which can grow the company’s EBITDA byupwards of 300 percent.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Monday's trading session at $2.47, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.265/$.

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

The State of Colorado has recently begun work on a bill to promotethe development of geothermal energy production within the state

Currently, geothermal plants provide less than 0.5% of the UnitedStates’ electricity output despite lacking the weather-related orsunshine-linked challenges faced by other renewable energy sources

Companies such as GeoSolar Technologies have sought to capitalizeupon geothermal energy’s constant, clean energy output within theirhome energy systems

Industry leaders have now called for geothermal energy productionto benefit from a similar subsidy programme as was granted to windand solar power in prior years

In early March, the United States’ Intergovernmental Panel onClimate Change released a report summarizing the key findings oftheir Sixth Assessment Cycle. Within the report lays a direwarning; world leaders would have to slash greenhouse gas emissionsby up to 60 percent by 2035 to have a 50 percent chance of limitingglobal warming to 15 degrees Celsius above pre-industrial levels,thus staving off sever climate impacts ( The State of Colorado is seeking to address that challengehead-on. During a recent workshop held in conjunction with the22-member Western Governors Association, Colorado Gov. Jared Polisrevealed that the state government was exploring how to furtherpromote the use of geothermal energy as source of electricity.GeoSolar Technologies (“GST”), a Colorado-based climate technology company pioneering anapproach into clean energy solutions for households has based itstechnological innovations along a similar logic. Whilst thecompany’s proprietary SmartGreen™ Home system – an environmentallyfriendly, renewable energy focused technological innovation whichseeks to power homes through carbon free energy sources, makes useof solar technology and panels as part of their home system, theheart of the SmartGreen™ Home system lays within geothermalground-based energy beneath the average home.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.


The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.


The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News


Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announcedthat it awarded the contract for clinical research organization(“CRO”) services to California-based InClin, Inc. for its expectedupcoming Food and Drug Administration (“FDA”)-registered, U.S.phase 1b Investigational New Drug (“IND”) hypertension studyHYPER-H23-1 with its patented DehydraTECH-powered cannabidiol(“DehydraTECH-CBD”). According to the announcement, HYPER-H23-1 isentitled “A Phase 1b Randomized, Double-Blind, Placebo-ControlledStudy of the Safety, Pharmacokinetics, and Pharmacodynamics ofDehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension.”The study’s primary objective will be to evaluate safety andtolerability in 120 hypertensive patients, and secondary objectiveswill include efficacy evaluation in reducing blood pressuretogether with detailed pharmacokinetic testing.

To view the full press release, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $2.26, off by 0.440529%, on 13,580 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$3.60.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused onmerging traditional therapeutics with psychedelic research, will bepart of the upcoming third annual Psychedelic Therapeutics and DrugDevelopment Conference. The company announced that vice presidentof R&D James Kuo, MD, will be presenting at the conference,which is scheduled to be held on May 15–16, 2023, in Burlington,California. Titled “The Ketamine Endgame,” Kuo’s presentation willinclude key information about ketamine and Silo Pharma’sinvolvement in the space; his presentation is scheduled to begin at1:05 p.m. PDT. According to the company, three of Silo Pharma’sfive novel drug candidates currently under development includeketamine as a primary therapeutic agent. The PsychedelicTherapeutics and Drug Development Conference is designed to gatherleaders and experts in an array of sectors, including research,academia, industry, nonprofit sector and government. Agenda itemswill include discussions about the challenges and opportunitiesfacing those engaged in the research and development ofpsychedelics for various health conditions with considerable unmetneed.

To view the full press release, visit

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Monday's trading session at $2.06, off by 3.7383%, on 14,844 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.71/$12.225.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies, Inc. (Nasdaq: FRGT) (“Fr8Tech”), a technology company whosecustom-developed Fr8App , an industry-leading freight-matching platform powered by AI andmachine-learning, offers a real-time portal for B2B cross-bordershipping and domestic shipping within the USMCA region, has beennamed BeatBox Beverages’ number one carrier for cross-bordershipments. BeatBox benefits from Fr8App's exceptional communicationand frequent updates, which improve the shipping process and offerunmatched levels of service and professionalism.Rita Garza, BeatBox Operations Manager said, “In just one month of service, BeatBox has experienced asignificant improvement in our cross border shipping process,thanks to Fr8App’s efficient and reliable services. Fr8App has beenan invaluable resource in helping with BeatBox’s logistics needs,and their ability to assist with cross-border shipments during thenight shift has been particularly impressive. In fact, BeatBox isalready considering using Fr8App for their third shift in additionto our day-time shifts. Fr8App has been easy to work with and thetools they have available to us, such as Fr8Radar for tracking ourshipments, have been a great value-add for our company. The team atBeatBox is thrilled with the results and looks forward to a deepand long term relationship with Fr8App.”

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Monday's trading session at $1.65, off by 7.3034%, on 139,883 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.3424/$31.512.

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

New research has found that pollutants found in the air may causeeczema in infants. Eczema, also referred to atopic dermatitis, is a condition that causes anindividual’s skin to become itchy and extremely dry. This skincondition affects more than 31 million Americans.Eczema often develops in infancy and peaks in early childhood. However, flare-ups may occur even inadults when an individual comes into contact with allergens such asdyes, pets, perfumes or even food. While it is common knowledgethat genetics may make one more susceptible to developing eczema, researchersare yet to determine its exact cause. However, a dramatic rise inthe condition’s incidence in industrialized nations since the ‘70s has left many researchers convinced that the environment may playa major role in causing eczema. Companies such as Jupiter Wellness Inc. (NASDAQ: JUPW) are also hard at work developing better treatments for eczema toprovide relief to those diagnosed with this condition.

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

  • Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
  • Psoriasis & VitiligoPhotocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
  • Jellyfish Protection SunscreenNoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
  • EczemaJW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
  • BurnsJW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
  • Cold SoresJW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
  • Sexual WellnessJW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • COVID-19-Induced TinnitusJW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that it will provide a business update andrelease its financial results for the first quarter of 2023following the close of the market on Tuesday, May 9, 2023. At 2:30p.m. PT on that same day, Cepton will hold a conference call andwebcast. Interested parties should dial 1-888-886-7786 (toll-free)or 1-416-764-8658 (international) to join the live call and visit to access the live webcast. A telephonic replay of the conferencecall will be available as detailed in the announcement.

To view the full press release, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $0.4043, off by 2.7424%, on 137,499 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.375/$3.10.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

Federal law in the United States makes it unlawful to use orpossess marijuana, but the majority of states have recentlylegalized it for either recreational or medical use. The shift inthe law has coincided with a sharp rise in public support for cannabis legalization. Based on surveys conducted by the Pew Research Center and othersources, we’ve highlighted seven key facts below concerningAmericans’ perceptions of and attitudes toward cannabis. As morecompanies such as IGC Pharma Inc. (NYSE American: IGC) venture into developing cannabis-based medicines that end up beingapproved by the FDA, attitudes to this plant could shift even moreaway from prohibition.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Monday's trading session at $0.3351, off by 6.9167%, on 82,521 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.8432.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

A law allowing adults 21 and above to purchase cannabis online has been approved by the ColoradoHouse. The action is intended to assist companies that have historicallyrelied on payments in cash, which exposes them to crime risk. Lastweek, the legislature voted 40 to 23 to approve the bill, which wasput forth by Democrats Said Sharbini, William Lindstedt and RobertRodriguez. The proposed legislation would add controls to allow for online sales while removingterminology from the current law that expressly forbids the sale ofcannabis over the internet. According to the law, shops mustconfirm the consumer’s identity and age before they make a purchaseonline, and that data must correspond to the proof of identity theypresent when they collect the goods. As the drug reform movementspreads, it will open numerous market opportunities for amultiplicity of companies such as Advanced Container Technologies Inc. (OTC: ACTX), which are only tangentially connected to marijuana or itsproducts.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Monday's trading session at $0.3, off by 1.6393%, on 417 volume. The average volume for the last 3 months is 18,174 and the stock's 52-week low/high is $0.073/$1.05.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announcedthat its majority owned subsidiary, Mullen Advanced EnergyOperations (“MAEO”), will today begin execution of a $680,000contract that was previously awarded by the District of Columbia,Washington, D.C., to EV Technologies, LLC. The contract covers thepurchase and installation of Energy Management Module (“EMM”) unitson Chevrolet Bolts within the D.C. city government’s vehicle fleet.“The D.C. city project is the first of many that we have plannedfor the new EMM technology,” said David Michery, CEO and chairmanof Mullen Automotive. “Municipal city fleets are a perfect use casefor EVs and even better with our Energy Management Modules addedfor extending vehicle range and performance. Ideally, the vehiclescan spend less time charging and more time in the local communitiesfor civic use and support.” To view the full news release, visit BDEW recently said that last year there was an increase of 35% in electric vehicle charger stations over the level required to meet the increasing numbers of batteryelectric vehicles being rolled out in Germany. Germany’sgovernment authorized a plan totaling $6.9 billion over the next three years in order torapidly increase the quantity of electric vehicle charging outletsas part of its effort towards carbon neutrality in the transportsector. This plan was launched in October last year. The plan setsa target of a million charging stations in 2030, compared to just70,000 at present — an increase of 14 times. The plan wouldconcentrate on constructing the chargers in small towns and citieswhere there is currently a shortage. If the charging network isexpanded at a similar rate in different markets, such as NorthAmerica, the uptake of electric vehicles from manufacturers suchas Mullen Automotive Inc. (NASDAQ: MULN) is likely to accelerate significantly in the coming years.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $0.096, off by 6.7055%, on 757,187,617 volume. The average volume for the last 3 months is 195.47M and the stock's 52-week low/high is $0.08/$1.71.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.


Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Monday's trading session at $0.48, even for the day. The average volume for the last 3 months is 36,227 and the stock's 52-week low/high is $0.25/$0.765.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.